Second-generation 12-LOX oral therapeutics

About Cadrenal Therapeutics

Cadrenal Therapeutics is a publicly traded, late-stage biopharma company focused on developing differentiated anticoagulant therapies for critical unmet needs. Its strategy targets niche, high-mortality conditions like HIT and anticoagulation in end-stage kidney disease patients, where current therapies are inadequate. The company has built a multi-asset pipeline with two Phase 3-ready candidates and has secured key regulatory designations to accelerate development and commercialization.

Therapeutic Areas